WAY-326766

CAS No. 853138-67-7

WAY-326766( —— )

Catalog No. M36981 CAS No. 853138-67-7

WAY-326766 increases ion transport through mutant CFTR and can be used to alter the lifespan of eukaryotes.WAY-326766 can be used to treat cystic fibrosis (CF).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 70 In Stock
10MG 117 In Stock
25MG 235 In Stock
50MG 327 In Stock
100MG 453 In Stock
200MG 611 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    WAY-326766
  • Note
    Research use only, not for human use.
  • Brief Description
    WAY-326766 increases ion transport through mutant CFTR and can be used to alter the lifespan of eukaryotes.WAY-326766 can be used to treat cystic fibrosis (CF).
  • Description
    WAY-326766 increases ion transport through mutant CFTR and can be used to alter the lifespan of eukaryotes.WAY-326766 can be used to treat cystic fibrosis (CF).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    CFTR
  • Recptor
    CFTR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    853138-67-7
  • Formula Weight
    397.42
  • Molecular Formula
    C21H23N3O5
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(C(NC=1C=C2C(=CC1)OCCO2)=O)(N(C(CNC(C)=O)=O)C)C3=CC=CC=C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Ivacaftor hydrate

    Ivacaftor (VX-770, VX770) is a potent, orally bioavailable CFTR potentiator, increases G551D- and F508del CFTR-mediated Cl- secretion with EC50 of 100 nM.

  • CFTR(inh)-172

    CFTRinh-172 is a voltage-independent, selective CFTR inhibitor with Ki of 300 nM.

  • Astressin 2B

    Potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist (IC50 values are 1.3 and > 500 nM for CRF2 and CRF1 respectively). Antagonizes CRF2-mediated inhibition of gastric emptying.